JAZZ stock forecast, quote, news & analysis
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology... Show more
Why Jazz Pharmaceuticals (JAZZ) Stock Is Down -11% in the Last 30 Days
Key Takeaways
- Jazz Pharmaceuticals (JAZZ) has declined roughly 11% over the past 30 days, falling from about $240.74 to the low-$210 range.
- The pullback occurred despite record second-quarter revenue and the U.S. FDA approval of the oncology drug Ziihera.
- The planned retirement of Chief Commercial Officer Samantha Pearce has added near-term execution uncertainty.
- Broader profit-taking and sector pressure on commercial mid-cap biotech names have amplified the decline.
- The stock remains higher by more than 50% on a one-year basis, indicating that much of the prior rally preceded the recent sell-off.
Jazz Pharmaceuticals (JAZZ) Company Overview and Market Position
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, focused on developing and commercializing medicines for serious, often rare diseases. Its diversified portfolio spans neuroscience, oncology, and epilepsy. Core neuroscience franchises include Xywav for narcolepsy and idiopathic hypersomnia and Epidiolex for certain seizure disorders, while its oncology portfolio features Zepzelca for small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and the recently approved Ziihera for HER2-positive biliary tract cancers.
Jazz has built a reputation for durable cash flows from its sleep and epilepsy franchises while reinvesting in an expanding oncology pipeline, including zanidatamab and dordaviprone. Investors follow the stock closely because of its blend of established revenue-generating products and meaningful pipeline catalysts.
Jazz Pharmaceuticals (JAZZ) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, JAZZ has fallen approximately 11%, moving from a closing price near $240.74 in mid-September to the low-$210 range by mid-to-late October. The decline was not a single-day event but a steady grind lower punctuated by higher-volume down days in early-to-mid October.
The three-month picture is similar. From a closing level of about $243.47 in mid-July, the stock has dropped roughly 12%, even though it first rallied to a 52-week intraday high near $266 in late August. In other words, the quarterly trend is characterized by a strong advance into late summer followed by a sharp reversal that has erased those gains and pushed the stock below its 50-day and 200-day moving averages.
What Drove JAZZ Stock Price in the Last 30 Days
Several factors contributed to the recent decline. First, the stock fell even as fundamentals improved. Jazz reported record second-quarter revenue of about $1.21 billion, up 16% year over year, and raised its full-year 2026 revenue guidance to a range of $4.60 billion to $4.75 billion. The company also received U.S. FDA approval for Ziihera in HER2-positive biliary tract cancer and lifted its peak sales outlook for the drug. Yet the shares declined after the earnings report, suggesting investors had already priced in much of the positive news following a powerful multi-month rally.
Second, leadership changes introduced execution risk. Jazz disclosed the planned retirement of Executive Vice President and Chief Commercial Officer Samantha Pearce, triggering a search for her successor and prompting some investors to reassess near-term commercial execution.
Third, broader market dynamics weighed on the name. Analysts have noted that commercial mid-cap biotech stocks broadly faced pressure as drug launch expectations ran ahead of fundamentals, contributing to sector-wide de-risking. Analyst actions were mixed: BofA raised its price target to $313, while RBC Capital trimmed its target to $296, both maintaining positive ratings.
What Drove JAZZ Stock Performance Over the Last Quarter
The broader quarterly narrative is one of a strong rally giving way to profit-taking. Through July and August, JAZZ climbed to a 52-week high near $266, driven by optimism around oncology launches, raised guidance, and a resilient sleep and epilepsy franchise. That advance left the stock with a one-year return exceeding 50%.
As the quarter progressed, the same catalysts that fueled the rally became sources of vulnerability. The post-earnings decline suggested a "sell the news" dynamic, while the commercial leadership transition and a cooler environment for mid-cap biotech names reinforced the pullback. The result was a round-trip in the quarterly chart, with the stock surrendering its late-summer gains and trading back toward levels last seen in the spring.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's top-performing automated trading bots. While Tickeron offers hundreds of AI-driven bots that trade thousands of tickers, only the most relevant and consistently strong performers are featured in this section. These bots differ in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term momentum to longer-horizon trend following. For investors seeking a data-driven perspective on names like JAZZ and the broader market, the page offers a convenient way to monitor which automated strategies are currently standing out.
JAZZ Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is Jazz's third-quarter earnings report, expected in early November 2026. Investors will focus on Xywav and Epidiolex trends, Ziihera launch uptake, and any updates to full-year 2026 guidance. Pipeline readouts for zanidatamab and dordaviprone, along with the resolution of the chief commercial officer succession, will also shape sentiment.
Beyond company-specific items, broader biotech risk appetite, potential generic and pricing pressure in the sleep franchise, and the pace of oncology launch execution remain key swing factors. These elements, rather than any single event, are likely to determine whether the stock stabilizes or extends its recent decline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for JAZZ turns negative, indicating new downward trend
JAZZ saw its Momentum Indicator move below the 0 level on September 23, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In 56 of the 96 cases, the stock moved further down in the following days. The odds of a decline are at 58%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for JAZZ entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JAZZ's RSI Oscillator exited the oversold zone, 19 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 66%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 178 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
JAZZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.866) is normal, around the industry mean (2.988). P/E Ratio (13.936) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
Industry Biotechnology